Cyllene Therapeutics raises €33 million to pursue HSV-based gene therapy after Krystal model

Cyllene Therapeutics, a French-US biotech, announced it has secured €33 million in financing.

The capital will be used to develop HSV-based gene therapy programs, aiming to replicate the approach pioneered by Krystal Biotech but targeting a different therapeutic indication.

The funding round underscores continued investor interest in viral vector gene therapies despite the field's technical challenges.